Hi Tech. Thanks for crunching the numbers. So, we are saying with a hypothetical 34.7% reduction in deaths with a p = .036 should be a lock for approval? MESO's trial for s/c Covid with mortality as a primary endpoint had a target efficacy of 43%. This target was selected based on their anecdotal experience. And as we all know, the trial was halted due to futility.

Would Cytodyn be held to the same standard by the FDA?